Oil prices have slumped to six-year lows as global stock markets continue to fall on concerns over a slowing Chinese economy, according to BBC.
Brent and US crude futures fell below $45 and $40 a barrel respectively as global investors assessed the contagion risks of China’s volatile stock market. BBC Reports
Recent data has suggested that China’s economic growth continues to slow down.
In addition to the volatility in Chinese shares, there are fears of a protracted effect on demand for commodities. BBC added.
Shares of Marathon Oil Corporation (NYSE:MRO), lost -2.48% to $15.73.
Marathon Oil Corporation operates as an energy company. It operates in three segments: North America Exploration and Production, International Exploration and Production, and Oil Sands Mining. The North America Exploration and Production segment explores for, produces, and markets crude oil and condensate, natural gas liquids, and natural gas in North America.
Shares of Macrocure Ltd (NASDAQ:MCUR), inclined 51.01% to $4.50, during its last trading session.
Macrocure Ltd, declared that a pre-specified, futility analysis conducted by the Data Safety Monitoring Board for CureXcell(R) — the Company’s lead product candidate in its Phase 3 pivotal clinical study (MC-105) for venous leg ulcers (VLU) — determined that this study is not predictable to meet its primary endpoint.
“While we are disdesignated with the results of the VLU futility analysis, given the positive clinical outcomes seen in our experience with more than 5,000 patients in Israel, we continue to believe that the technology has clinical merit for patients with chronic and other hard-to-heal wounds,” said Nissim Mashiach, President and Chief Executive Officer of Macrocure. “We will evaluate the data collected to date in the MC-105 study to determine an appropriate course of action, counting the potential initiation of a third Phase 3 study in patients with chronic wounds below the knee. We intend to work closely with the FDA to complete all additional clinical trial work required to pursue the approval and commercialization of CureXcell. Macrocure remains committed to both the technology and our ability to deliver this innovative solution to patients suffering from chronic hard-to-heal wounds. We remain on track with our guidance to report top-line study results from our pivotal, Phase III Diabetic Foot Ulcer (DFU) clinical trial in October 2015.”
Macrocure Ltd., a biotechnology company, focuses on developing, manufacturing, and commercializing novel cell therapy products for the treatment of chronic and other hard-to-heal wounds in Israel. Its lead cell-based biological product comprises CureXcell, which is in two Phase III clinical trials for the treatment of hard-to-heal diabetic foot ulcers and hard-to-heal venous leg ulcers. Macrocure Ltd. was founded in 2008 and is headquartered in Petach Tikva, Israel.
Finally, PepsiCo, Inc (NYSE:PEP), ended its last trade with -1.77% loss, and closed at $96.25.
PepsiCo, Inc. (PEP) declared that Hugh Johnston, Vice Chairman and Chief Financial Officer, Tom Greco, Chief Executive Officer, Frito-Lay North America, and Ramon Laguarta, Chief Executive Officer, Europe Sub-Saharan Africa, will present at the Barclays Back-to-School Consumer Conference in Boston on Wednesday, September 9, 2015 at about 8:15 a.m. EDT.
PepsiCo, Inc. operates as a food and beverage company worldwide. Its Frito-Lay North America segment offers Lays potato chips, Doritos tortilla chips, Cheetos cheese-flavored snacks, Tostitos tortilla chips, branded dips, Ruffles potato chips, Fritos corn chips, and Santitas tortilla chips.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
